Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUME-Lung 1: Nintedanib plus Docetaxel in Advanced NSCLC
NCT00805194Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2008
- Primary completion
- Nov 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing BIBF 1120 + Docetaxel with Placebo + Docetaxel (2 arms). Primary endpoint: Progression Free Survival. Started Dec 2008; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00805194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805194.